On May 30, 2024 Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer, reported that it will share data demonstrating the power of its DCISionRT test to better predict radiation therapy (RT) benefit in comparison to clinicopathologic risk factors for women with ductal carcinoma in situ (DCIS) at The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), to be held on May 31 – June 4, 2024 at the McCormick Place in Chicago (Press release, PreludeDx, MAY 30, 2024, View Source [SID1234643888]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Of particular importance, the DCISionRT biosignature identified a low-risk group of patients with no significant benefit from ET or RT after breast-conserving surgery.
"We look forward to sharing the latest data at ASCO (Free ASCO Whitepaper) that reaffirms DCISionRT’s prognostic and predictive value of the test to reclassify recurrence risk based on clinicopathology alone, and that the test’s impact is not altered by use of endocrine therapy," said Dan Forche, President and CEO of PreludeDx.
PreludeDx American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Poster to Be Presented
Title: Identification of DCIS patients with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature
Presenter: Pat W. Whitworth, MD, Nashville Breast Center, Nashville, TN
Date: Sunday, June 2, 9:00 a.m. CT
About DCISionRT for Breast DCIS
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman’s individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score that identifies a woman’s risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT’s intelligent reporting provides a woman’s recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.